An implantable Skin Cancer Vaccine goes to Human Clinical Trials

Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials

Novel Therapeutic Cancer Vaccine goes to Human Clinical Trials
The implantable vaccine is initially designed to target cancerous melanoma in skin, but might have application to other cancers

A team from Harvard and Dana-Farber has launched a Phase I clinical trial of a therapeutic melanoma vaccine designed to reprogram a patient’s immune system to destroy tumors. The vaccine consists of a small disk-like, biodegradable sponge that’s infused with signaling molecules and components of the patient’s tumor.

The disk-shaped, biodegradable sponge contains growth factors and components of each patient’s tumors. Researchers at the Wyss Institute and clinicians at Dana-Farber Cancer Institute hope that when it’s implanted under the patient’s skin, it will spur the immune system to attack and destroy tumors.

Read Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials
Wyss Institute, 6 Sep. 2013

Related: Novel Therapeutic Cancer Vaccine Goes to Human Clinical Trials, Science Daily, 6 Sep. 2013

6 thoughts on “An implantable Skin Cancer Vaccine goes to Human Clinical Trials”

  1. wow this is an amazing advance is cancer research. Seems like a great way to use the bodies natural defenses versus introducing unknown toxins or harm to the body.
    Sirena

Have your say ! Share your views